NRXS - NeurAxis Inc. Debt to Book Capitalization Ratio

Corporate company logo of NeurAxis, Inc. (NRXS)

NeurAxis, Inc. (NRXS) revenues depend on the rate of technology adoption in pediatrics. The company's debt-to-book capitalization ratio reflects current trends, where the value 0.04 indicates the current debt-to-equity magnitude. Expanding insurance coverage in the US is broadening the customer base, while a "razor-and-blade" model ensures stable margins through the continuous procurement of consumables by clinics.

NeurAxis, Inc. (NRXS) - Debts to Book Value from 02/21/2024 to 10/27/2026
Flagship merchandise of NeurAxis Inc

The financial stability of NeurAxis, Inc. (NRXS) is based on the balance between debt capital and equity. This metric compares total liabilities with the book value of equity to determine the degree of leverage. It is critical for investors to monitor this ratio to assess solvency while scaling the IB-Stim technology. Debt optimization allows the company to develop non-drug therapy without critical risks. By analyzing the dynamic debt-to-book capitalization ratio, one can judge the issuer's creditworthiness.

Competitors of NeurAxis, Inc.

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Debt to Book Capitalization Ratio Viking Therapeutics (VKTX)|Debt to Book Value Ratio supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value Denali DNLI|Debt to Book Value HRMY (Harmony Pharma)|Biohaven Corp - Debts to Book Capitalization|Debt to Book Capitalization Ratio Amylyx Pharmaceuticals (AMLX)|TRVI - Debt to Net Assets Ratio|PRAX: Debts to Book Capitalization|Debts to Book Capitalization Anavex|Debt to Book Value CeriBell Corp (CBLL)|Debt to Book Value Ratio prothena.com|ALEC (Alector, Inc.) - Debts to Book Capitalization|Debts to Net Assets ANNX (annexonbio.com)|Debt to Book Capitalization Ratio OMER|NGNE - Debts to Net Assets|Debt to Book Value AC Immune Corp (ACIU)|VYGR - Debt to Net Assets Ratio|Neumora Therapeutics - Debts to Book Capitalization|SCLX (scilexholding.com) - Debts to Net Assets|Debt to Book Capitalization Ratio Tevogen Bio (TVGN)|Debt to Book Value Ratio Alpha Cognition Corp|Debts to Book Capitalization CGTX (Cognition Therapeutics)|Debt to Book Value Inhibikase Pharma IKT|Debt to Book Value SAVA|Assertio Holdings - Debts to Net Assets|Coya (COYA) - Debt to Book Capitalization Ratio|VTGN: Debt to Book Value Ratio|Debt to Book Capitalization Ratio ovidrx.com OVID|Debt to Net Assets Ratio Acumen Pharmaceuticals, Inc|Debt to Book Value CervoMed Inc. (CRVO)|Debt to Book Value Ratio ATHE|CLNN (Clene Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets PEPG (pepgen.com)|JUNS - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Relmada Corp RLMD|ANVS (Annovis Bio, Inc.) - Debts to Book Capitalization|Grace Therapeutics, Inc. (GRCE) - Debts to Book Value|AIFF: Debt to Book Value|KLTO (Klotho Neurosciences) - Debts to Book Capitalization|NRSN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio RVPH|MetaVia Inc - Debt to Book Capitalization Ratio|Debts to Book Value HSDT (heliusmedical.com)|PASG - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Neuphoria Therapeutics, Inc. NEUP|NERV (Minerva Neurosciences Corp) - Debts to Book Capitalization|Athira Pharma Corp (ATHA) - Debts to Book Value|ADXN: Debt to Book Value|ALZN (Alzamend Neuro) - Debts to Book Capitalization|CYCN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Protagenic|Debts to Book Capitalization KTTA|Debts to Book Capitalization cortigent.com CRGT|ATXI - Debt to Book Value|Debt to Book Value Ratio brainstorm-cell.com BCLI|Debts to Book Capitalization CARA (Cara Therapeutics)|CHRO: Debts to Net Assets|eliemtx.com - Debt to Book Capitalization Ratio|Debts to Net Assets Intra-Cellular Therapies, Inc.|LBPH - Debt to Book Value|Debt to Net Assets Ratio marinuspharma.com|NKGN (NKGen Biotech) - Debts to Book Capitalization|Debts to Net Assets NRBO (NeuroBo Pharmaceuticals Inc)|SAGE - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Synaptogenix, Inc SNPX|TRVN: Debts to Book Capitalization|Vigil Neuroscience (VIGL) - Debt to Book Value|Anew Medical - Debt to Book Value|CERE (Cerevel Therapeutics Inc) - Debts to Net Assets